Minerva Neurosciences (NERV) Assets (2013 - 2026)
Minerva Neurosciences (NERV) posted Assets of $94.0 million for Q1 2026, down 4.02% on a QoQ basis from $98.0 million in Q4 2025, and up 186.68% year-over-year from $32.8 million in Q1 2025.
Minerva Neurosciences (NERV) Assets (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Assets history runs 14 years deep, the most recent figure standing at $94.0 million for Q1 2026.
- Quarterly Assets rose 186.68% year-over-year to $94.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.0 million (up 186.68% YoY) and the FY2025 annual result came in at $98.0 million, up 163.76% from the prior year.
- Assets was $94.0 million for Q1 2026 at Minerva Neurosciences, down from $98.0 million in the prior quarter.
- Across five years, Assets topped out at $98.0 million in Q4 2025 and bottomed at $28.1 million in Q3 2025.
- A 5-year average of $55.8 million and a median of $55.1 million in 2022 frame the typical range for Assets.
- Annual changes were most pronounced in 2022 — Assets plunged 38.75% — and 2026, when it soared 186.68%.
- Minerva Neurosciences' Assets stood at $55.1 million in 2022, then advanced by 3.29% to $56.9 million in 2023, then slumped by 34.72% to $37.1 million in 2024, then soared by 163.76% to $98.0 million in 2025, then declined by 4.02% to $94.0 million in 2026.
- Business Quant data shows NERV's Assets at $94.0 million in Q1 2026, $98.0 million in Q4 2025, and $28.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - | 311.58 Mn |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | 78.88 Mn |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | 33.89 Mn |
| 4 | BeOne Medicines | 472.06 Bn | 467.27 Bn | 1.35 Bn | 8.55 Bn |
| 5 | Vertex Pharmaceuticals | 122.10 Bn | 114.85 Bn | 2.59 Bn | 26.48 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.25 Bn | 3.31 Bn | 40.87 Bn |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | 811.27 Mn |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | 10.03 Bn |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.50 Bn | 959.66 Mn | 5.13 Bn |
| 10 | Minerva Neurosciences | 186.14 Mn | 186.14 Mn | - | 94.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 94.03 Mn |
| Dec 31, 2025 | 97.97 Mn |
| Sep 30, 2025 | 28.09 Mn |
| Jun 30, 2025 | 30.42 Mn |
| Mar 31, 2025 | 32.80 Mn |
| Dec 31, 2024 | 37.14 Mn |
| Sep 30, 2024 | 42.81 Mn |
| Jun 30, 2024 | 46.29 Mn |
| Mar 31, 2024 | 50.51 Mn |
| Dec 31, 2023 | 56.90 Mn |
| Sep 30, 2023 | 63.13 Mn |
| Jun 30, 2023 | 67.14 Mn |
| Mar 31, 2023 | 51.59 Mn |
| Dec 31, 2022 | 55.09 Mn |
| Sep 30, 2022 | 59.76 Mn |
| Jun 30, 2022 | 64.96 Mn |
| Mar 31, 2022 | 70.62 Mn |
| Dec 31, 2021 | 77.12 Mn |
| Sep 30, 2021 | 97.56 Mn |
| Jun 30, 2021 | 105.32 Mn |